SI1602370T1 - Sinergistične kombinacuje, ki vsebujejo reninskiinhibitor, za kardiovaskularne bolezni - Google Patents

Sinergistične kombinacuje, ki vsebujejo reninskiinhibitor, za kardiovaskularne bolezni

Info

Publication number
SI1602370T1
SI1602370T1 SI200130850T SI200130850T SI1602370T1 SI 1602370 T1 SI1602370 T1 SI 1602370T1 SI 200130850 T SI200130850 T SI 200130850T SI 200130850 T SI200130850 T SI 200130850T SI 1602370 T1 SI1602370 T1 SI 1602370T1
Authority
SI
Slovenia
Prior art keywords
renin inhibitor
cardiovascular diseases
synergistic combinations
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
SI200130850T
Other languages
English (en)
Slovenian (sl)
Inventor
William Hewitt
Daniel Lucius Vasella
Randy Lee Webb
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9903412&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1602370(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SI1602370T1 publication Critical patent/SI1602370T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
SI200130850T 2000-11-17 2001-11-15 Sinergistične kombinacuje, ki vsebujejo reninskiinhibitor, za kardiovaskularne bolezni SI1602370T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0028151A GB0028151D0 (en) 2000-11-17 2000-11-17 Combination of organic compounds
EP20050015603 EP1602370B1 (en) 2000-11-17 2001-11-15 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases

Publications (1)

Publication Number Publication Date
SI1602370T1 true SI1602370T1 (sl) 2008-10-31

Family

ID=9903412

Family Applications (3)

Application Number Title Priority Date Filing Date
SI200131026T SI1915993T1 (sl) 2000-11-17 2001-11-15 Sinergistične kombinacije, ki obsegajo reninski inhibitor, za kardiovaskularne bolezni
SI200130850T SI1602370T1 (sl) 2000-11-17 2001-11-15 Sinergistične kombinacuje, ki vsebujejo reninskiinhibitor, za kardiovaskularne bolezni
SI200130530T SI1341533T1 (sl) 2000-11-17 2001-11-15 Sinergisticne kombinacije vsebujoce reninski inhibitor za kardiovaskularne bolezni

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI200131026T SI1915993T1 (sl) 2000-11-17 2001-11-15 Sinergistične kombinacije, ki obsegajo reninski inhibitor, za kardiovaskularne bolezni

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200130530T SI1341533T1 (sl) 2000-11-17 2001-11-15 Sinergisticne kombinacije vsebujoce reninski inhibitor za kardiovaskularne bolezni

Country Status (31)

Country Link
US (4) US8168616B1 (enExample)
EP (7) EP1930000A1 (enExample)
JP (6) JP2004513920A (enExample)
KR (6) KR101008752B1 (enExample)
CN (4) CN100404024C (enExample)
AT (2) ATE317692T1 (enExample)
AU (2) AU2002223680B2 (enExample)
BR (1) BR0115411A (enExample)
CA (2) CA2763223A1 (enExample)
CY (5) CY1105603T1 (enExample)
CZ (2) CZ305341B6 (enExample)
DE (3) DE60134349D1 (enExample)
DK (3) DK1341533T3 (enExample)
EC (1) ECSP034603A (enExample)
ES (4) ES2256335T3 (enExample)
GB (1) GB0028151D0 (enExample)
HU (2) HUP0301841A3 (enExample)
IL (3) IL155707A (enExample)
LU (2) LU91563I2 (enExample)
MX (1) MXPA03004358A (enExample)
NL (2) NL300385I1 (enExample)
NO (2) NO334002B1 (enExample)
NZ (6) NZ568764A (enExample)
PL (3) PL400915A1 (enExample)
PT (3) PT1341533E (enExample)
RU (2) RU2310443C2 (enExample)
SG (1) SG135969A1 (enExample)
SI (3) SI1915993T1 (enExample)
SK (1) SK287881B6 (enExample)
WO (1) WO2002040007A1 (enExample)
ZA (1) ZA200303497B (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003035046A2 (en) * 2001-10-18 2003-05-01 Novartis Ag Salts formed of an at1-receptor antagonist and a cardiovascular agent
ES2369216T3 (es) 2002-05-17 2011-11-28 Novartis Pharma Ag Composición farmacéutica que comprende un inhibidor de renina, un bloqueador del canal de calcio y un diurético.
GB0212410D0 (en) 2002-05-29 2002-07-10 Novartis Ag Organic compounds
AU2003255527A1 (en) * 2002-06-28 2004-01-19 Speedel Pharma Ag Pharmaceutical formulation comprising non-peptide renin inhibitor and surfactant
JP2005537822A (ja) * 2002-06-28 2005-12-15 ノバルティス アクチエンゲゼルシャフト 有機化合物の使用
SE0300988D0 (sv) * 2003-04-03 2003-04-03 Astrazeneca Ab New use
TW200900399A (en) 2003-10-01 2009-01-01 Speedel Experimenta Ag Organic compounds
GB0325605D0 (en) * 2003-11-03 2003-12-10 Novartis Ag Combination of organic compounds
CN1882528A (zh) * 2003-11-26 2006-12-20 诺瓦提斯公司 有机化合物
GB0327839D0 (en) * 2003-12-01 2003-12-31 Novartis Ag Organic compounds
ATE472524T1 (de) * 2004-01-23 2010-07-15 Novartis Ag Diaminoalkohole und deren verwendung als renininhibitoren
PT1756037E (pt) * 2004-01-23 2011-02-25 Novartis Ag Derivados de aminoálcoois e a sua actividade como inibidores de renina
AR047445A1 (es) 2004-01-23 2006-01-18 Speedel Experimenta Ag Compuestos derivados de amino alcohol con actividad inhibidora de la renina y su uso en composiciones farmaceuticas.
MY148773A (en) * 2004-03-17 2013-05-31 Novartis Ag Galenic formulations of organic compounds
WO2005089731A2 (en) * 2004-03-17 2005-09-29 Novartis Ag Use of renin inhibitors in therapy
EP1725530A1 (en) * 2004-03-19 2006-11-29 Speedel Experimenta AG Organic compounds
WO2005099695A1 (en) * 2004-04-19 2005-10-27 Novartis Ag Drug delivery systems for the prevention and treatment of vascular diseases
WO2006041974A1 (en) * 2004-10-08 2006-04-20 Novartis Ag Use of renin inhibitors for the prevention or treatment of diastolic dysfunction or diastolic heart failure
GB0428250D0 (en) * 2004-12-23 2005-01-26 Novartis Ag Organic compounds
MY146830A (en) * 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
TW200722424A (en) 2005-03-31 2007-06-16 Speedel Experimenta Ag Substituted piperidines
EP1897879A3 (en) 2005-03-31 2008-06-11 Speedel Experimenta AG 2,4,5-substituted piperidines as renin inhibitors
AU2006241219A1 (en) * 2005-04-27 2006-11-02 Novartis Ag Methods of treating atherosclerosis
GB0511686D0 (en) * 2005-06-08 2005-07-13 Novartis Ag Organic compounds
CN1732952B (zh) * 2005-09-02 2010-04-07 姚俊华 一种治疗高血压的复方分散片
ES2303198T3 (es) * 2005-09-28 2008-08-01 Teva Pharmaceutical Industries Ltd. Combinaciones estables de besilato de amlodipina e hidrocloruro de benazeprilo.
US8158146B2 (en) 2005-09-28 2012-04-17 Teva Pharmaceutical Industries Ltd. Stable combinations of amlodipine besylate and benazepril hydrochloride
WO2007056324A2 (en) * 2005-11-08 2007-05-18 Novartis Ag Combination of an angiotensin ii receptor blocker, a calcium channel blocker and another active agent
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
KR20080104149A (ko) * 2006-03-13 2008-12-01 엔싸이시브 파마슈티칼즈 인코퍼레이티드 확장기 심장 부전의 치료를 위한 방법 및 조성물
US20070260203A1 (en) * 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
GB0612540D0 (en) 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
TW200831463A (en) * 2006-09-12 2008-08-01 Speedel Experimenta Ag Nitrate esters of aminoalcohols
KR100888131B1 (ko) * 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
BRPI0721167A2 (pt) * 2006-12-15 2014-03-18 Novartis Ag Inibidores de renina para prevenção e tratamento de hipertensão em pacientes obesos.
US20080194626A1 (en) * 2007-02-14 2008-08-14 Gorczynski Richard J Antihypertensive drug combination
AU2008309058B2 (en) * 2007-09-28 2012-08-09 Novartis Ag Galenical formulations of Aliskiren and Valsartan
EP2062874B1 (en) 2007-11-20 2014-12-17 KRKA, tovarna zdravil, d.d., Novo mesto Process and intermediates for the preparation of aliskiren
CN102014881A (zh) 2008-02-22 2011-04-13 韩兀生物制药株式会社 药物制剂
WO2009125981A2 (ko) 2008-04-10 2009-10-15 한올제약주식회사 약제학적 제제
WO2009127251A1 (en) * 2008-04-16 2009-10-22 Novartis Ag Combinations comprising a renin inhibitor
EP2281557A4 (en) 2008-04-29 2011-08-31 Hanall Biopharma Co Ltd PHARMACEUTICAL FORMULATION CONTAINING AN ANGIOTENSIN II RECEPTOR BLOCKING AGENT
WO2010024772A1 (en) * 2008-08-29 2010-03-04 Medivir Ab Aspartyl protease inhibitors
SI2189442T1 (sl) 2008-11-20 2015-03-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Postopek in intermediati za pripravo aliskirena
KR20110130491A (ko) 2009-03-20 2011-12-05 노파르티스 아게 발사르탄 및 알리스키렌의 고정 용량 조합물의 생약 제형
CN101926793B (zh) * 2010-08-05 2012-08-15 成都自豪药业有限公司 一种含替米沙坦和阿利吉伦的联合用药物及其制备方法
WO2012152718A1 (en) 2011-05-06 2012-11-15 Farmicom Pharmaceutical Company D.O.O. Composition comprising angiotensin ii receptor antagonist and antioxidant for maintaining and/or improving skin properties
RU2483750C1 (ru) * 2012-03-19 2013-06-10 Общество с ограниченной ответственностью "СупраГен" Способ лечения больных с острым инфарктом миокарда с подъемом сегмента st
NZ724002A (en) * 2012-05-18 2017-07-28 Luoda Pharma Pty Ltd Liquid formulation comprising propylene glycol and an ace inhibitor
RU2554815C1 (ru) * 2014-06-18 2015-06-27 Общество с ограниченной ответственностью "Нанолек" Гипотензивное средство
US20170216213A1 (en) 2014-07-30 2017-08-03 Merck Patent Gmbh Directly compressible polyvinyl alcohols
BR112019007954A2 (pt) * 2016-10-27 2019-07-02 Damian Pharma Ag inibidor da aldosterona sintase

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4889861A (en) 1982-12-21 1989-12-26 Ciba-Geigy Corp. Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
US4617307A (en) 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
US4559332A (en) 1983-04-13 1985-12-17 Ciba Geigy Corporation 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof
US4782043A (en) 1983-06-15 1988-11-01 Merck & Co., Inc. Renin inhibitors containing a C-terminal amide cycle
US4898729A (en) 1983-12-09 1990-02-06 Euroceltique, S.A. Treatment of hypertension, compounds and compositions for antihypertension and diuresis
US4812442A (en) 1984-05-29 1989-03-14 Merck & Co., Inc. Tripeptide renin inhibitors
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US5594021A (en) 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
US4927807A (en) 1987-10-06 1990-05-22 Abbott Laboratories Glaucoma treatment
SE8802428D0 (sv) * 1988-06-28 1988-06-28 Haessle Ab New compounds
US5268374A (en) 1988-10-04 1993-12-07 Abbott Laboratories Non-peptide renin inhibitors
US5164388A (en) 1988-10-19 1992-11-17 Abbott Laboratories Heterocyclic peptide renin inhibitors
ATE190051T1 (de) 1989-06-14 2000-03-15 Smithkline Beecham Corp Imidazoalkensäure
EP0438311A3 (en) * 1990-01-19 1992-07-01 Merck & Co. Inc. Di- and tripeptide renin inhibitors
US5182266A (en) * 1990-01-31 1993-01-26 Abbott Laboratories Method for treating renal disease
DE122010000024I1 (de) * 1990-02-19 2010-07-08 Novartis Ag Acylverbindungen
PT97078B (pt) 1990-03-20 1997-07-31 Sanofi Sa Processo para a preparacao de derivados heterociclicos n-substituidos e de composicoes farmaceuticas que os contem
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
IE68045B1 (en) 1990-05-11 1996-05-15 Abbott Lab Renin inhibitors
US5821232A (en) 1990-05-11 1998-10-13 Pfizer Inc. Synergistic therapeutic compositions and methods
KR970005839B1 (ko) * 1990-05-11 1997-04-21 화이자 인코포레이티드 상승 치료효과를 얻기 위한 조성물 및 방법
WO1992000972A1 (en) 1990-07-11 1992-01-23 Abbott Laboratories Renin inhibiting compounds
WO1992003429A1 (en) * 1990-08-15 1992-03-05 Abbott Laboratories Renin inhibitors
US5656650A (en) * 1990-12-14 1997-08-12 Smithkline Beecham Corp. Angiotensin II receptor blocking compositions
JP3398379B2 (ja) 1990-12-14 2003-04-21 スミスクライン・ビーチャム・コーポレイション アンジオテンシンｉｉ受容体遮断組成物
EP0498361A3 (en) 1991-02-06 1992-09-02 Schering Corporation Combination of an angiotensin ii antagonist or renin inhibitor with a neutral endopeptidase inhibitor
IE920540A1 (en) 1991-02-21 1992-08-26 Sankyo Co 1-biphenylmethylimidazole derivatives, their preparation and¹their therapetuic use
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
DE4121975A1 (de) 1991-07-03 1993-01-07 Basf Ag Thermoplastische formmassen auf der basis von polycarbonaten, styrol/acrylnitril-polymerisaten und polyolefinen
US5256667A (en) * 1991-09-25 1993-10-26 Merck & Co., Inc. Quinazolinones and pyridopyrimidinones
TW226375B (enExample) 1991-10-24 1994-07-11 American Home Prod
US6057344A (en) 1991-11-26 2000-05-02 Sepracor, Inc. Methods for treating hypertension, and angina using optically pure (-) amlodipine
KR100331667B1 (ko) 1993-04-27 2002-11-08 스미스클라인 비참 코포레이션 엔도텔린수용체길항제
US5508272A (en) 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
ES2154277T3 (es) * 1993-07-15 2001-04-01 Hoffmann La Roche Combinacion farmaceutica que contiene un inhibidor del sistema renina-angiotensina y un antagonista de endotelina.
ES2156157T3 (es) 1993-08-18 2001-06-16 Banyu Pharma Co Ltd Derivado de ciclopenteno heteroaromatico fusionado con una actividad antagonista de la endotelina.
US5606078A (en) 1994-04-18 1997-02-25 Ciba-Geigy Corporation 3,5-Disubstituted tetrahydrofuran-2-ones
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
US5659065A (en) 1994-04-18 1997-08-19 Novartis Corporation Alpha-aminoalkanoic acids and reduction products
US5562921A (en) 1994-07-15 1996-10-08 Sherman; Bernard C. Stable solid pharmaceutical compositions containing enalapril maleate
JP3741441B2 (ja) 1994-08-19 2006-02-01 アボツト・ラボラトリーズ エンドセリン・アンタゴニスト
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
TW313568B (enExample) 1994-12-20 1997-08-21 Hoffmann La Roche
CZ223697A3 (en) 1995-01-27 1997-12-17 Rhone Poulenc Rorer Ltd Substituted phenyl derivatives as endothelin antagonists
US5846990A (en) 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
JPH0971586A (ja) * 1995-09-07 1997-03-18 Yamanouchi Pharmaceut Co Ltd 新規な二環性縮合イミダゾール誘導体
US5696166A (en) 1995-10-31 1997-12-09 Yanni; John M. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
ATE201202T1 (de) 1995-12-20 2001-06-15 Yamanouchi Pharma Co Ltd Arylethensulfonamid-derivate und diese enthaltende medikamente
IT1277737B1 (it) 1995-12-28 1997-11-12 Zambon Spa Derivati tiolici ad attivita' inibitrice delle metallopeptidasi
WO1997027314A1 (fr) 1996-01-23 1997-07-31 Shionogi & Co., Ltd. Processus de production d'analogues d'acide oleanolique par la culture de racine pileuse
JP3345891B2 (ja) 1996-04-04 2002-11-18 萬有製薬株式会社 エンドセリン拮抗薬を含有することを特徴とする心不全治療剤
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
DE19806438A1 (de) * 1998-02-17 1999-08-19 Basf Ag Neue Carbonsäurederivate mit 5-substituiertem Pyrimidinring, ihre Herstellung und Verwendung
CA2332608C (en) * 1998-06-17 2010-03-23 Bristol-Myers Squibb Company Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination
EP1098634A4 (en) 1998-07-20 2006-10-25 Smithkline Beecham Corp EPROSARTAN CONTAINING MORE EFFECTIVE FORMULATIONS IN ORAL SOLID PHARMACEUTICAL FORM
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
EP1175246A4 (en) * 1999-03-19 2004-12-15 Brigham & Womens Hospital POSITIVE REGULATION OF NITRIC OXIDE SYNTHASE OF TYPE III ENDOTHELIAL CELLS BY HMG-COA REDUCTASE INHIBITORS
ES2288487T3 (es) 1999-11-09 2008-01-16 Pharmacia Corporation Uso de eplerenona para tratamiento de la restenosis.
US20030114389A1 (en) * 2001-11-13 2003-06-19 Webb Randy Lee Combination of organic compounds
ES2369216T3 (es) * 2002-05-17 2011-11-28 Novartis Pharma Ag Composición farmacéutica que comprende un inhibidor de renina, un bloqueador del canal de calcio y un diurético.
ATE397147T1 (de) 2002-12-31 2008-06-15 Volkswagen Ag Verfahren zur steuerung einer verbrennungskraftmaschine sowie magerlauffahige verbrennungskraftmaschine

Also Published As

Publication number Publication date
IL212075A (en) 2013-08-29
PL400915A1 (pl) 2012-12-17
SK287881B6 (sk) 2012-02-03
RU2006132668A (ru) 2008-03-20
SI1341533T1 (sl) 2006-08-31
KR20080011355A (ko) 2008-02-01
AU2368002A (en) 2002-05-27
NL300385I1 (nl) 2009-07-01
KR20080097488A (ko) 2008-11-05
KR20110063596A (ko) 2011-06-10
MXPA03004358A (es) 2003-08-19
EP1341533B1 (en) 2006-02-15
JP6577994B2 (ja) 2019-09-18
HU230882B1 (hu) 2018-11-29
DE60117295T2 (de) 2006-08-17
US9023894B2 (en) 2015-05-05
IL155707A0 (en) 2003-11-23
CY1114829T1 (el) 2015-11-04
CN101091703A (zh) 2007-12-26
EP2305232B1 (en) 2019-07-17
PL361404A1 (en) 2004-10-04
NL301005I2 (nl) 2019-10-29
NO2013019I2 (no) 2013-12-17
IL155707A (en) 2012-02-29
DE122009000021I1 (de) 2009-08-06
ES2256335T3 (es) 2006-07-16
CA2763223A1 (en) 2002-05-23
NZ550896A (en) 2008-06-30
PT1915993E (pt) 2013-10-14
HUP0301841A2 (hu) 2003-09-29
JP6089278B2 (ja) 2017-03-08
EP2305231A1 (en) 2011-04-06
NL301005I1 (enExample) 2019-09-10
ES2429292T3 (es) 2013-11-14
CY1105603T1 (el) 2010-07-28
CN100404024C (zh) 2008-07-23
EP1602370A3 (en) 2005-12-14
EP1915993B1 (en) 2013-07-10
CY2013045I1 (el) 2015-11-04
ZA200303497B (en) 2004-04-28
DK1602370T3 (da) 2008-09-22
NZ537691A (en) 2007-01-26
US9023893B2 (en) 2015-05-05
CZ305341B6 (cs) 2015-08-05
EP1930000A1 (en) 2008-06-11
JP2009235107A (ja) 2009-10-15
US8618174B2 (en) 2013-12-31
JP6603757B2 (ja) 2019-11-06
RU2310443C2 (ru) 2007-11-20
KR20030051753A (ko) 2003-06-25
BR0115411A (pt) 2004-08-17
CA2428647A1 (en) 2002-05-23
HK1115544A1 (en) 2008-12-05
CY2013045I2 (el) 2015-11-04
EP2305232A1 (en) 2011-04-06
CZ299749B6 (cs) 2008-11-12
CY2009005I2 (el) 2012-01-25
US20120010295A1 (en) 2012-01-12
EP1915993A1 (en) 2008-04-30
CN1474690A (zh) 2004-02-11
WO2002040007A1 (en) 2002-05-23
NZ568764A (en) 2009-11-27
DE60134349D1 (de) 2008-07-17
EP2305233A1 (en) 2011-04-06
NO20032233L (no) 2003-05-16
NZ525795A (en) 2005-03-24
AU2002223680B2 (en) 2005-04-07
JP2004513920A (ja) 2004-05-13
SG135969A1 (en) 2007-10-29
NZ550897A (en) 2008-03-28
NO20032233D0 (no) 2003-05-16
LU92315I2 (fr) 2014-01-27
DE60117295D1 (de) 2006-04-20
US8168616B1 (en) 2012-05-01
HK1089356A1 (en) 2006-12-01
PT1341533E (pt) 2006-06-30
ECSP034603A (es) 2003-06-25
EP1602370A2 (en) 2005-12-07
JP2018030894A (ja) 2018-03-01
DK1341533T3 (da) 2006-05-08
EP1341533A1 (en) 2003-09-10
ES2308347T3 (es) 2008-12-01
NO334002B1 (no) 2013-11-11
ATE317692T1 (de) 2006-03-15
JP2018131465A (ja) 2018-08-23
IL217847A0 (en) 2012-03-29
HUP0301841A3 (en) 2010-07-28
EP1602370B1 (en) 2008-06-04
JP6373931B2 (ja) 2018-08-15
CY1108305T1 (el) 2012-01-25
HK1059212A1 (en) 2004-06-25
DK1915993T3 (da) 2013-10-14
ES2734523T3 (es) 2019-12-10
CY2009005I1 (el) 2012-01-25
HU1400409D0 (hu) 2003-09-29
ATE397445T1 (de) 2008-06-15
JP2013213061A (ja) 2013-10-17
CN101264072A (zh) 2008-09-17
KR20100114904A (ko) 2010-10-26
CN101264073A (zh) 2008-09-17
PL227576B1 (pl) 2017-12-29
US20120004312A1 (en) 2012-01-05
NO2013019I1 (no) 2014-06-02
PT1602370E (pt) 2008-09-10
RU2346703C2 (ru) 2009-02-20
SK5842003A3 (en) 2003-11-04
KR101258365B1 (ko) 2013-04-30
JP2017019876A (ja) 2017-01-26
NZ550898A (en) 2008-07-31
SI1915993T1 (sl) 2013-10-30
KR101008752B1 (ko) 2011-01-14
US20120016035A1 (en) 2012-01-19
KR20080096715A (ko) 2008-10-31
PL400914A1 (pl) 2012-12-17
LU91563I2 (fr) 2009-07-06
GB0028151D0 (en) 2001-01-03
IL212075A0 (en) 2011-06-30

Similar Documents

Publication Publication Date Title
NL301005I1 (enExample)
HUP0102281A3 (en) Prodrugs of dipeptidyl peptidase iv inhibitors, pharmaceutical compositions comprising thereof and their use
IL148630A0 (en) Compounds and pharmaceutical compositions for inhibiting cathepsin s
HUP9601566A2 (en) Therapeutic tetrahydro-isoquinolin derivatives, their intermediates and pharmaceutical compositions containing the active component
BG106586A (en) Pyrazolopyramidines as therapeutic agents
HUP0200881A2 (en) Renin inhibitors, process for preparation of the compounds, pharmaceutical compositions containing them and their use
HUP0102255A3 (en) Vla-4 inhibitor omepupa-v, pharmaceutical compositions comprising thereof and their use
CA2386793A1 (en) New selective retinoid agonists
GB9907571D0 (en) Compounds
EP0870502A3 (en) Use of adenosine uptake inhibitors for the manufacture of a medicament for the treatment of pancreatitis
EP0978287A4 (en) MEDICAL COMPOSITION CONTAINING AS GP34 INHIBITOR BINDING INHIBITOR.
CA2370501A1 (en) Pharmaceutical composition for the therapy of lower urinary tract symptoms
IL135993A0 (en) Pharmaceutical composition for the treatment of fibrosis
IL136687A0 (en) Pharmaceutical composition for the treatment of multiple sclerosis
IL127227A0 (en) A pharmaceutical composition for the treatment of multiple sclerosis